✦ LIBER ✦

Infliximab: additional benefits in Crohn's disease

Book ID: 120862506
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2002
Weight: 181 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200213490-00038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infliximab in Fistulizing Crohn's Diseas

Infliximab in Fistulizing Crohn's Disease

✍ Osterman, Mark T.; Lichtenstein, Gary R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Risks and Benefits of Infliximab for the

Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease

✍ Siegal, C.A. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 34 KB

Infliximab dose intensification in Crohn

Infliximab dose intensification in Crohn's disease

✍ Miguel Regueiro; Benjamin Siemanowski; Kevin E. Kip; Scott Plevy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

Background: Crohn's disease (CD) patients who lose response to infliximab may benefit from an increase in dose or decrease in interval between infusions. The aims of this study were to determine the proportion of CD patients who require dose intensification and factors associated with dose intensifi

Immunogenicity of Infliximab in Crohn's

Immunogenicity of Infliximab in Crohn's Disease

📂 Article 📅 2003 🏛 Massachusetts Medical Society 🌐 English ⚖ 66 KB

Infliximab tolerability in Crohn’s disea

Infliximab tolerability in Crohn’s disease patients

✍ Gary R. Lichtenstein; Greg Keenan; Mary Glenn Vreeland; Donny M. Chen 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 27 KB

Infliximab promising in paediatric Crohn

Infliximab promising in paediatric Crohn's disease

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 139 KB